<DOC>
	<DOCNO>NCT00643760</DOCNO>
	<brief_summary>The purpose study determine whether gabapentin enacarbil ( XP13512/GSK1838262 ) , hereafter refer GEn effective treatment neuropathic pain associate diabetic peripheral neuropathy ( DPN )</brief_summary>
	<brief_title>A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy ( DPN )</brief_title>
	<detailed_description>This dose-response study XP13512 compare concurrent placebo control LYRICA ( pregabalin ) , subject neuropathic pain associate DPN . Three dose XP13512 ( 1200 mg/day , 2400 mg/day 3600 mg/day ) evaluate management neuropathic pain associate DPN . Approximately 392 subject 70 80 participate site US randomize receive either XP13512 mention dos , placebo pregabalin ( 300mg/day ) .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Inclusion criterion : 18 year old Female subject eligible enter nonchildbearing potential lactating , negative pregnancy test agree use specify highly effective method avoid pregnancy Documented medical diagnosis Type 1 2 diabetes include : Stable glycemic control 3 month define &lt; 25 % change routine insulin , &lt; 50 % change routine oral antidiabetic agent dose HbA1c &lt; 8 % . ( HbA1c 8 11 % eligible attempt improve diabetic control fail ) DPN define : Bilateral reduce absent reflex ankle , Bilateral impair vibration , pinprick , fine touch temperature perception distal low extremity And Persistent distal burning dull pain foot , Persistent proximal ache pain leg , Paroxysmal electric , shoot , stab pain , Dysasthesias , Evoked pain And history pain least six month great five year attribute DPN ( refers duration pain ) Baseline 24hour average daily pain intensity score &gt; 4.0 measure 11 point pain intensity numerical rating scale Provides write informed consent accordance applicable regulatory requirement Exclusion criterion : Other chronic pain condition associate DPN . However , subject exclude : The pain condition locate different region body , The pain intensity condition great pain intensity DPN , The subject ass DPN independently pain condition . Other cause neuropathy low extremity pain Is unable discontinue prohibit medication nondrug therapy procedure throughout duration study Hepatic impairment define ALT AST &gt; 2x upper limit normal ( ULN ) alkaline phosphatase bilirubin &gt; 1.5x ULN Chronic hepatitis B C Impaired renal function define either creatinine clearance &lt; 60 mL/min require hemodialysis Corrected QT ( QTc ) interval &gt; 450 msec QTc interval &gt; 480 msec patient Bundle Branch Block Uncontrolled hypertension screen ( sit systolic &gt; 160 mmHg and/or sit diastolic &gt; 90 mmHg Current diagnosis active epilepsy active seizure disorder require chronic therapy antiepileptic drug ( ) Medical condition disorder would interfere action , absorption , distribution , metabolism , excretion GEn pregabalin , , investigator 's judgment : Is consider clinically significant could pose safety concern , Could interfere accurate assessment safety efficacy , , Could potentially affect subject 's safety study outcome Meets criterion define DSM‑IV‑TR major depressive episode active significant psychiatric disorder within last year Depression remission , without antidepressant treatment , may participate , unless stable antidepressant regimen prohibit medication Antidepressant medication may change discontinue met entry criterion must stable least 3 month prior enrollment History clinically significant drug alcohol abuse ( DSM‑IV‑TR ) . Benzodiazepines atypical benzodiazepine hypnotic sleep agent permit Currently participate another clinical study subject , expose investigational noninvestigational drug device Has participate clinical study expose investigational noninvestigational drug device : Within precede month study unrelated DPN , Within six month study relate DPN Treated previously GEn History allergic medically significant adverse reaction investigational product ( include gabapentin pregabalin ) excipients , acetaminophen related compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Peripheral Diabetic Neuropathy ( PDN )</keyword>
	<keyword>Neuropathic Pain</keyword>
</DOC>